Dominique Prié
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Dominique Prié has a total of 165 co-authors. Here are the top co-authors by number of shared publications:
- Gérard Friedlander
Weizmann Institute of Science
9 shared publications Marie Courbebaisse
Université Paris Descartes, Sorbonne-Paris-Cité, Faculté de Médecine, Paris
4 shared publications- Dominique Eladari
AP-HP, Hôpital Européen Georges Pompidou, Physiology Department, Paris Descartes University, and INSERM, Unit 970, Paris, France
3 shared publications - Frank Bienaimé
Université Paris Cité, Faculté de Médecine; AP-HP; Service de Physiologie Hôpital Necker Enfants-Malades, Assistance Publique-Hôpitaux de Paris, 75015 Paris, France; Institut Necker Enfants Malades-INEM, Département Croissance et Signalisation', INSERM UMR1151, CNRS UMR 8253, Paris, France
3 shared publications Pablo Ureña Torres
Service de néphrologie et dialyse, clinique du Landy, Saint-Ouen, France
3 shared publications- Bruno Moulin
Department of Nephrology and Transplantation, Strasbourg University Hospital, Strasbourg, France
2 shared publications
Latest Publications
- Open Access
- 9 October 2024
- Published by Wolters Kluwer Health in Kidney360
- Vol. 5 (12) , 1902-1912
Extracellular Fluid Volume and Mortality after Kidney Transplantation
Key Points: Post-transplantation extracellular fluid volume (ECV) is not only influenced by recipient characteristics and allograft function, but also by transplantation-specific factors. In multivariable cause-specific Cox analyses, increased ECV 3 months after kidney transplantation is independently associated with all-cause mortality but not graft loss. Multivariable linear regression further identified increased 3-month ECV as an independent predictor of reduced GFR measurement at 12 months. Background: High extracellular fluid volume (ECV) is associated with an increased risk of death in nontransplanted patients with CKD. By contrast, both the determinants and the prognosis value of ECV in kidney transplant recipients remain unclear. Methods: We studied a bicentric prospective cohort of 2057 kidney transplant recipients who underwent GFR measurement (mGFR) 3 months after transplantation. We calculated ECV from iohexol plasma disappearance curve and analyzed its association with patient's characteristics and outcomes. Results: The mean ECV and mGFR were 14.6±2.6 L/1.73 m2 and 52±16 ml/min per 1.73 m2, respectively. Multiple linear regression identified male sex, older donor and recipient ages, deceased donor, nonpreemptive transplantation, diabetes, cardiac arrhythmia, heart failure, proteinuria, and higher mGFR as independent factors associated with increased ECV. In multivariable cause-specific Cox analyzes, higher tertiles of ECV were associated with increased mortality (tertile 1 as reference; hazard ratio [95% confidence interval] for tertile 2: 1.65 [1.11 to 2.47]; tertile 3: 1.80 [1.18 to 2.74]) but not graft loss. Increased ECV, 3 months after transplantation, was a predictor of reduced mGFR at 12 months after adjusting for 3-month mGFR and other confounding factors (β coefficient: −0.06; 95% confidence interval [−0.09 to −0.02]). Conclusions: An elevated ECV 3 months after kidney transplantation is independently associated with increased mortality and decreased mGFR at 12 months, but not with graft loss.
- 9 October 2024
- Published by Wolters Kluwer Health in Kidney360
- Vol. 5 (12) , 1902-1912
Open AccessExtracellular Fluid Volume and Mortality after Kidney Transplantation
Key Points: Post-transplantation extracellular fluid volume (ECV) is not only influenced by recipient characteristics and allograft function, but also by transplantation-specific factors. In multivariable cause-specific Cox analyses, increased ECV 3 months after kidney transplantation is independently associated with all-cause mortality but not graft loss. Multivariable linear regression further identified increased 3-month ECV as an independent predictor of reduced GFR measurement at 12 months. Background: High extracellular fluid volume (ECV) is associated with an increased risk of death in nontransplanted patients with CKD. By contrast, both the determinants and the prognosis value of ECV in kidney transplant recipients remain unclear. Methods: We studied a bicentric prospective cohort of 2057 kidney transplant recipients who underwent GFR measurement (mGFR) 3 months after transplantation. We calculated ECV from iohexol plasma disappearance curve and analyzed its association with patient's characteristics and outcomes. Results: The mean ECV and mGFR were 14.6±2.6 L/1.73 m2 and 52±16 ml/min per 1.73 m2, respectively. Multiple linear regression identified male sex, older donor and recipient ages, deceased donor, nonpreemptive transplantation, diabetes, cardiac arrhythmia, heart failure, proteinuria, and higher mGFR as independent factors associated with increased ECV. In multivariable cause-specific Cox analyzes, higher tertiles of ECV were associated with increased mortality (tertile 1 as reference; hazard ratio [95% confidence interval] for tertile 2: 1.65 [1.11 to 2.47]; tertile 3: 1.80 [1.18 to 2.74]) but not graft loss. Increased ECV, 3 months after transplantation, was a predictor of reduced mGFR at 12 months after adjusting for 3-month mGFR and other confounding factors (β coefficient: −0.06; 95% confidence interval [−0.09 to −0.02]). Conclusions: An elevated ECV 3 months after kidney transplantation is independently associated with increased mortality and decreased mGFR at 12 months, but not with graft loss.
- 1 December 2023
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 309 (3) , e230567
Glomerular Filtration Rate Measured Based on Iomeprol Clearance Assessed at CT Urography in Living Kidney Donor Candidates
Background Estimating glomerular filtration rate (GFR) from serum creatinine can be inaccurate, and current procedures for measuring GFR are time-consuming and cumbersome. Purpose To develop a method for measuring GFR based on iomeprol clearance assessed at CT urography in kidney donor candidates and compare this with iohexol clearance (reference standard for measuring GFR). Materials and Methods This cross-sectional retrospective study included data from kidney donor candidates who underwent both iohexol clearance and CT urography between July 2016 and October 2022. CT-measured GFR was calculated as the iomeprol excretion rate in the urinary system between arterial and excretory phases (Hounsfield units times milliliters per minute) divided by a surrogate for serum iomeprol concentration in the aorta at the midpoint (in Hounsfield units). Performance of CT-measured GFR was assessed with use of mean bias (mean difference between CT-measured GFR and iohexol clearance), precision (the distance between quartile 1 and quartile 3 of the bias [quartile 3 minus quartile 1], with a small value indicating high precision), and accuracy (percentage of CT-measured GFR values falling within 10%, 20%, and 30% of iohexol clearance values). Intraobserver agreement was assessed for 30 randomly selected individuals with the Lin concordance correlation coefficient. Results A total of 75 kidney donor candidates were included (mean age, 51 years ± 13 [SD]; 45 female). The CT-measured GFR was unbiased (1.1 mL/min/1.73 m2 [95% CI: -1.9, 4.1]) and highly precise (16.2 mL/min/1.73 m2 [quartiles 1 to 3, -6.6 to 9.6]). The accuracy of CT-measured GFR within 10%, 20%, and 30% was 61.3% (95% CI: 50.3, 72.4), 88.0% (95% CI: 80.7, 95.4), and 100%, respectively. Concordance between CT-based GFR measurements taken 2 months apart was almost perfect (correlation coefficient, 0.99 [95% CI: 0.98, 0.99]). Conclusion In living kidney donors, GFR measured based on iomeprol clearance assessed at CT urography showed good agreement with GFR measured based on iohexol clearance. © RSNA, 2023 Supplemental material is available for this article. See also the editorial by Davenport in this issue.
- 1 December 2023
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 309 (3) , e230567
Glomerular Filtration Rate Measured Based on Iomeprol Clearance Assessed at CT Urography in Living Kidney Donor Candidates
Background Estimating glomerular filtration rate (GFR) from serum creatinine can be inaccurate, and current procedures for measuring GFR are time-consuming and cumbersome. Purpose To develop a method for measuring GFR based on iomeprol clearance assessed at CT urography in kidney donor candidates and compare this with iohexol clearance (reference standard for measuring GFR). Materials and Methods This cross-sectional retrospective study included data from kidney donor candidates who underwent both iohexol clearance and CT urography between July 2016 and October 2022. CT-measured GFR was calculated as the iomeprol excretion rate in the urinary system between arterial and excretory phases (Hounsfield units times milliliters per minute) divided by a surrogate for serum iomeprol concentration in the aorta at the midpoint (in Hounsfield units). Performance of CT-measured GFR was assessed with use of mean bias (mean difference between CT-measured GFR and iohexol clearance), precision (the distance between quartile 1 and quartile 3 of the bias [quartile 3 minus quartile 1], with a small value indicating high precision), and accuracy (percentage of CT-measured GFR values falling within 10%, 20%, and 30% of iohexol clearance values). Intraobserver agreement was assessed for 30 randomly selected individuals with the Lin concordance correlation coefficient. Results A total of 75 kidney donor candidates were included (mean age, 51 years ± 13 [SD]; 45 female). The CT-measured GFR was unbiased (1.1 mL/min/1.73 m2 [95% CI: -1.9, 4.1]) and highly precise (16.2 mL/min/1.73 m2 [quartiles 1 to 3, -6.6 to 9.6]). The accuracy of CT-measured GFR within 10%, 20%, and 30% was 61.3% (95% CI: 50.3, 72.4), 88.0% (95% CI: 80.7, 95.4), and 100%, respectively. Concordance between CT-based GFR measurements taken 2 months apart was almost perfect (correlation coefficient, 0.99 [95% CI: 0.98, 0.99]). Conclusion In living kidney donors, GFR measured based on iomeprol clearance assessed at CT urography showed good agreement with GFR measured based on iohexol clearance. © RSNA, 2023 Supplemental material is available for this article. See also the editorial by Davenport in this issue.
- Open Access
- 9 January 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 23 (3) , 366-376
Nonskeletal and skeletal effects of high doses versus low doses of vitamin D3 in renal transplant recipients: Results of the VITALE (VITamin D supplementation in renAL transplant recipients) study, a randomized clinical trial
- 9 January 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 23 (3) , 366-376
Open AccessNonskeletal and skeletal effects of high doses versus low doses of vitamin D3 in renal transplant recipients: Results of the VITALE (VITamin D supplementation in renAL transplant recipients) study, a randomized clinical trial
- Open Access
Urinary collagen-derived peptides as sensitive markers for bone resorption and bisphosphonate treatment in kidney transplant patients
Kidney transplant recipients (KTR) are at increased risk of fractures. Total urinary hydroxyproline excretion used to be a marker for bone resorption (BR) but faded into the background when more specific markers like Beta-CrossLaps (CTX) became available. Proteomic studies identified numerous hydroxyproline-containing urinary collagen peptides but their origin remains unknown. We followed the hypothesis that some of the urinary collagen peptides are associated with BR and are markers for pathophysiological changes in bone metabolism of KTR. Clinical and laboratory data including serum levels of CTX in 96 KTR from two French centers (Strasbourg, n=38; Paris-Necker, n=58) were correlated with the signal intensity of urinary peptides identified by capillary electrophoresis (CE) coupled to mass spectrometry (MS) and tandem-MS. The effect of oral bisphosphonates on urinary peptides was studied in an independent group of 11 KTR. Eighty-two urinary peptides were identified to be significantly correlated with serum CTX levels in both cohorts. Statistical association with parameters other than BR markers were not significant. Collagen α-1(I) chain (COL1A1) was the most frequently identified peptide source. COL1A1 peptides associated with BR were significantly more hydroxylated than those showing no association (55.9% versus 45,2%, p2 -test). From the 82 urinary peptides correlated to CTX, 17 were significantly associated with bisphosphonate treatment. All of these 17 peptides showed a marked reduction in their excretion levels after 410 ± 344 days of bisphosphonate treatment compared to baseline levels. We studied the cleavage sites of these COL1A1 peptides and observed a signature of Cathepsin K and Matrix Metallopeptidase 9. This study provides strong evidence for the occurrence of collagen peptides in the urine of KTR that are associated with BR and that are sensitive to bisphosphonate treatment. Their assessment might become a valuable tool to monitor bone status in KTR.
Open AccessUrinary collagen-derived peptides as sensitive markers for bone resorption and bisphosphonate treatment in kidney transplant patients
Kidney transplant recipients (KTR) are at increased risk of fractures. Total urinary hydroxyproline excretion used to be a marker for bone resorption (BR) but faded into the background when more specific markers like Beta-CrossLaps (CTX) became available. Proteomic studies identified numerous hydroxyproline-containing urinary collagen peptides but their origin remains unknown. We followed the hypothesis that some of the urinary collagen peptides are associated with BR and are markers for pathophysiological changes in bone metabolism of KTR. Clinical and laboratory data including serum levels of CTX in 96 KTR from two French centers (Strasbourg, n=38; Paris-Necker, n=58) were correlated with the signal intensity of urinary peptides identified by capillary electrophoresis (CE) coupled to mass spectrometry (MS) and tandem-MS. The effect of oral bisphosphonates on urinary peptides was studied in an independent group of 11 KTR. Eighty-two urinary peptides were identified to be significantly correlated with serum CTX levels in both cohorts. Statistical association with parameters other than BR markers were not significant. Collagen α-1(I) chain (COL1A1) was the most frequently identified peptide source. COL1A1 peptides associated with BR were significantly more hydroxylated than those showing no association (55.9% versus 45,2%, p2 -test). From the 82 urinary peptides correlated to CTX, 17 were significantly associated with bisphosphonate treatment. All of these 17 peptides showed a marked reduction in their excretion levels after 410 ± 344 days of bisphosphonate treatment compared to baseline levels. We studied the cleavage sites of these COL1A1 peptides and observed a signature of Cathepsin K and Matrix Metallopeptidase 9. This study provides strong evidence for the occurrence of collagen peptides in the urine of KTR that are associated with BR and that are sensitive to bisphosphonate treatment. Their assessment might become a valuable tool to monitor bone status in KTR.
- Top Cited PapersOpen Access
- 1 January 2022
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 42 (1) , 3-23
Hormone Immunoassay Interference: A 2021 Update
Khaldoun Ghazal, Pharm., Ph.D., Severine Brabant, M.D., Dominique Prie, M.D., Ph.D., and Marie-Liesse Piketty, Pharm., Ph.D.. Ann Lab Med 2022;42:3-23. https://doi.org/10.3343/alm.2022.42.1.3
- 1 January 2022
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 42 (1) , 3-23
Top Cited PapersOpen AccessHormone Immunoassay Interference: A 2021 Update
Khaldoun Ghazal, Pharm., Ph.D., Severine Brabant, M.D., Dominique Prie, M.D., Ph.D., and Marie-Liesse Piketty, Pharm., Ph.D.. Ann Lab Med 2022;42:3-23. https://doi.org/10.3343/alm.2022.42.1.3
- 1 June 2021
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 82 (3-4) , 141-143
FGF23 and Cardiovascular Risk
- 1 June 2021
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 82 (3-4) , 141-143
FGF23 and Cardiovascular Risk
- Open Access
- 19 March 2021
- Published by Wolters Kluwer Health in European Journal of Anaesthesiology
- Vol. 38 (6) , 652-658
Evaluation of glomerular filtration rate using iohexol plasma clearance in critically ill patients with augmented renal creatinine clearance
BACKGROUND: Augmented renal creatinine clearance (ARC) (≥130 ml min−1 1.73 m−2) is frequent in intensive care unit (ICU) patients and may impact patient outcome. OBJECTIVES: To compare glomerular filtration rate (GFR) measured with iohexol plasma clearance and creatinine clearance in critically ill patients with augmented renal clearance. DESIGN: Single-centre, retrospective study. SETTING: French University Hospital ICU from November 2016 to May 2019. PATIENTS: Adult patients with augmented renal clearance who had a measurement of iohexol plasma clearance. MAIN OUTCOME MEASURE: Agreement between 6 h creatinine clearance (6 h CrCl) and iohexol plasma clearance (GFRio). RESULTS: Twenty-nine patients were included. The median 6 h creatinine clearance was 195 [interquartile range (IQR) 162 to 251] ml min−1 1.73 m−2 and iohexol clearance was 133 [117 to 153] ml min−1 1.73 m−2. Sixteen patients (55%) had hyperfiltration (clearance >130 ml min−1 1.73 m−2) measured with iohexol clearance. Mean bias between iohexol and creatinine clearance was −80 [limits of agreement (LoA) −216 to 56 ml min−1 1.73 m−2]. For Cockcroft and Gault Modification of Diet in Renal Disease equation (MDRD), Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI) formulae, mean biases were, respectively −27 (LoA −99 to 45), −14 (LoA −86 to 59) and 15 (LoA −33 to 64) ml min−1 1.73 m−2. CONCLUSION: In the present study, we found that in patients with augmented renal creatinine clearance, half of the patients do not have hyperfiltration using iohexol clearance measurements. We observed an important bias between 6 h CrCl and GFRio with large LoA. In critically patients with ARC, 6 h CrCl does not reliably estimate GFR and 6 h CrCl nearly systematically overestimates renal function. Comparison of creatinine-based GFR estimations and GFRio show acceptable bias but wide LoA.
- 19 March 2021
- Published by Wolters Kluwer Health in European Journal of Anaesthesiology
- Vol. 38 (6) , 652-658
Open AccessEvaluation of glomerular filtration rate using iohexol plasma clearance in critically ill patients with augmented renal creatinine clearance
BACKGROUND: Augmented renal creatinine clearance (ARC) (≥130 ml min−1 1.73 m−2) is frequent in intensive care unit (ICU) patients and may impact patient outcome. OBJECTIVES: To compare glomerular filtration rate (GFR) measured with iohexol plasma clearance and creatinine clearance in critically ill patients with augmented renal clearance. DESIGN: Single-centre, retrospective study. SETTING: French University Hospital ICU from November 2016 to May 2019. PATIENTS: Adult patients with augmented renal clearance who had a measurement of iohexol plasma clearance. MAIN OUTCOME MEASURE: Agreement between 6 h creatinine clearance (6 h CrCl) and iohexol plasma clearance (GFRio). RESULTS: Twenty-nine patients were included. The median 6 h creatinine clearance was 195 [interquartile range (IQR) 162 to 251] ml min−1 1.73 m−2 and iohexol clearance was 133 [117 to 153] ml min−1 1.73 m−2. Sixteen patients (55%) had hyperfiltration (clearance >130 ml min−1 1.73 m−2) measured with iohexol clearance. Mean bias between iohexol and creatinine clearance was −80 [limits of agreement (LoA) −216 to 56 ml min−1 1.73 m−2]. For Cockcroft and Gault Modification of Diet in Renal Disease equation (MDRD), Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI) formulae, mean biases were, respectively −27 (LoA −99 to 45), −14 (LoA −86 to 59) and 15 (LoA −33 to 64) ml min−1 1.73 m−2. CONCLUSION: In the present study, we found that in patients with augmented renal creatinine clearance, half of the patients do not have hyperfiltration using iohexol clearance measurements. We observed an important bias between 6 h CrCl and GFRio with large LoA. In critically patients with ARC, 6 h CrCl does not reliably estimate GFR and 6 h CrCl nearly systematically overestimates renal function. Comparison of creatinine-based GFR estimations and GFRio show acceptable bias but wide LoA.
- 22 July 2020
- Published by Springer Nature in Basic Research in Cardiology
- Vol. 115 (5) , 1-19
Fibroblast growth factor 23 decreases PDE4 expression in heart increasing the risk of cardiac arrhythmia; Klotho opposes these effects
The concentration of fibroblast growth factor 23 (FGF23) rises progressively in renal failure (RF). High FGF23 concentrations have been consistently associated with adverse cardiovascular outcomes or death, in chronic kidney disease (CKD), heart failure or liver cirrhosis. We identified the mechanisms whereby high concentrations of FGF23 can increase the risk of death of cardiovascular origin. We studied the effects of FGF23 and Klotho in adult rat ventricular cardiomyocytes (ARVMs) and on the heart of mice with CKD. We show that FGF23 increases the frequency of spontaneous calcium waves (SCWs), a marker of cardiomyocyte arrhythmogenicity, in ARVMs. FGF23 increased sarcoplasmic reticulum Ca2+ leakage, basal phosphorylation of Ca2+-cycling proteins including phospholamban and ryanodine receptor type 2. These effects are secondary to a decrease in phosphodiesterase 4B (PDE4B) in ARVMs and in heart of mice with RF. Soluble Klotho, a circulating form of the FGF23 receptor, prevents FGF23 effects on ARVMs by increasing PDE3A and PDE3B expression. Our results suggest that the combination of high FGF23 and low sKlotho concentrations decreases PDE activity in ARVMs, which favors the occurrence of ventricular arrhythmias and may participate in the high death rate observed in patients with CKD.
- 22 July 2020
- Published by Springer Nature in Basic Research in Cardiology
- Vol. 115 (5) , 1-19
Fibroblast growth factor 23 decreases PDE4 expression in heart increasing the risk of cardiac arrhythmia; Klotho opposes these effects
The concentration of fibroblast growth factor 23 (FGF23) rises progressively in renal failure (RF). High FGF23 concentrations have been consistently associated with adverse cardiovascular outcomes or death, in chronic kidney disease (CKD), heart failure or liver cirrhosis. We identified the mechanisms whereby high concentrations of FGF23 can increase the risk of death of cardiovascular origin. We studied the effects of FGF23 and Klotho in adult rat ventricular cardiomyocytes (ARVMs) and on the heart of mice with CKD. We show that FGF23 increases the frequency of spontaneous calcium waves (SCWs), a marker of cardiomyocyte arrhythmogenicity, in ARVMs. FGF23 increased sarcoplasmic reticulum Ca2+ leakage, basal phosphorylation of Ca2+-cycling proteins including phospholamban and ryanodine receptor type 2. These effects are secondary to a decrease in phosphodiesterase 4B (PDE4B) in ARVMs and in heart of mice with RF. Soluble Klotho, a circulating form of the FGF23 receptor, prevents FGF23 effects on ARVMs by increasing PDE3A and PDE3B expression. Our results suggest that the combination of high FGF23 and low sKlotho concentrations decreases PDE activity in ARVMs, which favors the occurrence of ventricular arrhythmias and may participate in the high death rate observed in patients with CKD.
- 29 March 2018
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 103 (6) , 2319-2328
Hepatic Production of Fibroblast Growth Factor 23 in Autosomal Dominant Polycystic Kidney Disease
Context The bone-derived hormone fibroblast growth factor (FGF) 23 controls phosphate homeostasis and urinary phosphate excretion. FGF23 plasma levels increase in the early stage of renal insufficiency to prevent hyperphosphatemia. Recent evidence suggests that this increase has effects on cardiac and immune cells that compromise patients’ health. Patients with autosomal dominant polycystic kidney disease (ADPKD) have been reported to have higher FGF23 concentrations than other patients with similar renal function. The significance of this finding has remained unknown. Methods and Results Analyzing the FGF23 plasma levels in 434 patients with ADPKD and 355 control subjects with a measured glomerular filtration rate (mGFR) between 60 and 120 mL/min per 1.73 m2, we confirmed that patients with ADPKD had higher FGF23 plasma concentrations than controls. Remarkably, this difference did not translate into renal phosphate leakage. Using different assays for FGF23, we found that this discrepancy was explained by a predominant increase in the cleaved C-terminal fragment of FGF23, which lacks phosphaturic activity. We found that FGF23 plasma concentration independently correlated with the severity of cystic liver disease in ADPKD. We observed that, in contrast to control liver tissues, the cystic liver from patients with ADPKD markedly expressed FGF23 messenger RNA and protein. In line with this finding, the surgical reduction of polycystic liver mass was associated with a decrease in FGF23 plasma levels independently of any modification in mGFR, phosphate, or iron status. Conclusion Our findings demonstrate that severely polycystic livers produce FGF23 and increase levels of circulating FGF23 in patients with ADPKD.
- 29 March 2018
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 103 (6) , 2319-2328
Hepatic Production of Fibroblast Growth Factor 23 in Autosomal Dominant Polycystic Kidney Disease
Context The bone-derived hormone fibroblast growth factor (FGF) 23 controls phosphate homeostasis and urinary phosphate excretion. FGF23 plasma levels increase in the early stage of renal insufficiency to prevent hyperphosphatemia. Recent evidence suggests that this increase has effects on cardiac and immune cells that compromise patients’ health. Patients with autosomal dominant polycystic kidney disease (ADPKD) have been reported to have higher FGF23 concentrations than other patients with similar renal function. The significance of this finding has remained unknown. Methods and Results Analyzing the FGF23 plasma levels in 434 patients with ADPKD and 355 control subjects with a measured glomerular filtration rate (mGFR) between 60 and 120 mL/min per 1.73 m2, we confirmed that patients with ADPKD had higher FGF23 plasma concentrations than controls. Remarkably, this difference did not translate into renal phosphate leakage. Using different assays for FGF23, we found that this discrepancy was explained by a predominant increase in the cleaved C-terminal fragment of FGF23, which lacks phosphaturic activity. We found that FGF23 plasma concentration independently correlated with the severity of cystic liver disease in ADPKD. We observed that, in contrast to control liver tissues, the cystic liver from patients with ADPKD markedly expressed FGF23 messenger RNA and protein. In line with this finding, the surgical reduction of polycystic liver mass was associated with a decrease in FGF23 plasma levels independently of any modification in mGFR, phosphate, or iron status. Conclusion Our findings demonstrate that severely polycystic livers produce FGF23 and increase levels of circulating FGF23 in patients with ADPKD.
- Open Access
- 27 October 2016
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 102 (2) , e33-e35
Carboxy-terminal fragment of fibroblast growth factor 23 induces heart hypertrophy in sickle cell disease
- 27 October 2016
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 102 (2) , e33-e35
Open AccessCarboxy-terminal fragment of fibroblast growth factor 23 induces heart hypertrophy in sickle cell disease